Home > Boards > Free Zone > Penny Fundamentals > DD Support Board and Fraud Research Team

PRTN - FDA approval rumors

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
samsamsamiam Member Profile samsamsamiam Member Level 
Thursday, August 30, 2012 1:53:31 PM
Re: samsamsamiam post# 30522 Post # of 44253 
PRTN - FDA approval rumors


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79099318

FROM THE APS EMAIL:


Quote:
--------------------------------------------------------------------------------
It’s safe to say that if and when the FDA approval comes through, our members will be laughing their way to the bank as they leave the current trading price of $0,38 far in the past. Think about it, it is very likely that a treatment will hit the market very soon, which responds to a complaint that every women has at some point or another. We don’t need to tell you what this will do to your investment.
--------------------------------------------------------------------------------



If they announce the FDA approval next month, it will bust $1 easily. APS highlighted that in their email, huuuummmm.... makes ya wonder if they already have some BIG news they are waiting to release....

$PRTN

===============
Here's a hot flash -
Do these clowns have any idea of the time frame of clinical trials to approval with the FDA????


http://clinicaltrials.gov/

Found 228 studies with search of:

hot flashes


Nothing even submitted yet related to Tropine 3


---------------
BEVERLY HILLS, Calif., Aug. 29, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that the Company has retained clinical trial veteran Dr. David L. Stark, D.C., Q.M.E., CCRA, to develop and oversee FDA compliant trials of Tropine 3 for non-hormonal treatment of hot flashes in menopausal women.


----------
Same guy as this:


Stem Cell Therapy International, Inc. (OTCBB: SCII) and Histostem Corp. (Korea Histostem).

Stem Cell Therapy International (SCII) announced today it has appointed Dr. David L. Stark as president in anticipation of the upcoming merger with Histostem of Korea, one of the world’s leading umbilical cord stem cell blood banks and research companies in the field of stem cell treatments for various illnesses. After the closing of the merger between SCII and Histostem the name of the combined entities will be changed to AmStem International Corporation and Dr. Stark will continue in his capacity as president and member of the board of directors. Dr. Hoon Han of Histostem will be chairman of the board and CEO of AmStem International.

redOrbit (http://s.tt/16YLG)




http://investorshub.advfn.com/AmStem-Corporation-(fka-AMST)-120/




Amstem - revoked

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72385504


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist